Multiple organ dysfunction syndrome

SPEVIGO® approved for expanded indications in China and the US

Retrieved on: 
화요일, 3월 19, 2024
Arthralgia, Urinary tract infection, Uncertainty, Human, NMPA, Psoriasis, Disease, Multiple organ dysfunction syndrome, Incidence, Risk, GPP, Boehringer Ingelheim, Patient, Ageing, Executive officer, Immunoglobulin G, Anxiety, Doctor of Philosophy, MD, Quality of life, Flare, Injection site reaction, Clinical trial, Skin, Fever, Immune system, Pain, Itch, Food, FDA, Yale University, Fear

In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.

Key Points: 
  • In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.
  • “Until now, people living with GPP have not had any approved options to treat their disease,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, Yale University and Central Connecticut Dermatology.
  • “Experiencing GPP can be mentally and physically devastating, leaving those affected with uncertainty and fear of the next episode.
  • Therefore, expanding the treatment of GPP is a critical step towards addressing patients’ needs.”

Asep Medical Confirms the Use of AI - Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics

Retrieved on: 
목요일, 3월 14, 2024
Diagnosis, Stem cell, Dicarboxylic acid, Dental implant, Health, Dentistry, Gene, University, Chair, UBC, Erosion, Sepsis, Prevalence, Multiple organ dysfunction syndrome, Risk, COVID-19, Inflammation, Patient, Artificial intelligence, Bacteria, DSM-IV codes, AI, Death, Biofilm, Staphylococcus aureus, LASSO, Infection, Pathology, Therapy, ICU, FDA, The Lancet, Peptide

These markets include oral health (dental) care4, wounds5 and chronic rhinosinusitis6, all addressed by Asep peptides that show excellent activity in model infections.

Key Points: 
  • These markets include oral health (dental) care4, wounds5 and chronic rhinosinusitis6, all addressed by Asep peptides that show excellent activity in model infections.
  • AI was also used to simplify the extreme complexity7 of sepsis, which has limited treatments to date.
  • While others are trying to figure out how AI can be best used, we are already using it with amazing success in diagnostics and therapeutics.
  • Asep Inc. is dedicated to leveraging AI's power to improve human health," said Dr. Evan Haney, Chief Scientific Officer of Asep.

SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024

Retrieved on: 
월요일, 3월 11, 2024
Chronic kidney disease, FAAP, Multiple organ dysfunction syndrome, Medical director, Critical care, FDA, CKRT, SCD, Hospital, Risk, Conference, University, SeaStar, Acute kidney injury, AKI, CRRT, Nephrology, Pharmaceutical industry

DENVER, March 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces its sponsorship of an Industry Symposium titled “New Therapies in Pediatric Acute Kidney Injury” on March 13, 2024 at the 29th International Conference on Advances in Critical Care Nephrology – Updates in ICU Medicine: Controversies, Challenges and Solutions (AKI & CRRT 2024). The hybrid in-person and virtual conference is being held March 12-15 in San Diego.

Key Points: 
  • The hybrid in-person and virtual conference is being held March 12-15 in San Diego.
  • “Despite advancements in kidney replacement therapy, mortality rates in children with acute kidney injury (AKI) and multi-organ failure requiring continuous kidney replacement therapy (CKRT) remain at about 50%, and children who survive an AKI episode are at elevated risk of chronic kidney disease.
  • “It’s exciting to have recognized leaders in AKI and nephrology who serve on the SeaStar Medical Scientific Advisory Board participate in this symposium.
  • The discussion will highlight our technology, clinical data and the recent FDA approval of the SCD-PED, the first therapeutic device in our Quelimmune product family,” said Kevin Chung, MD, SeaStar Medical’s Chief Medical Officer.

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

Retrieved on: 
수요일, 1월 17, 2024
Mortality, Death, Patient, Incidence, ICU, Cytokine adsorbing column, Vasoplegic syndrome, Semmelweis University, Professional corporation, DRS, European Society of Cardiology, RCT, Heart, Standard of care, Pelvic floor dysfunction, Cytosorbents Corporation, Circulatory system, Risk, Organ dysfunction, VS, Multiple organ dysfunction syndrome, Observational study, Shock, Randomized controlled trial, ESC, Dentistry

In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.

Key Points: 
  • In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.
  • In a prior observational study , CytoSorb was associated with the reduced severity of vasoplegia in heart transplant patients, in addition to other clinical benefits.
  • In this prospective, single-center, open-label RCT, 60 heart transplant recipients were randomly assigned to either receive intraoperative CytoSorb hemoadsorption or standard of care.
  • Now, Nemeth, Soltesz, and colleagues have confirmed many of these observations in this rigorous and well-designed groundbreaking randomized controlled trial in orthotopic heart transplant patients.

EQS-News: Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)

Retrieved on: 
토요일, 12월 30, 2023
Urinary tract infection, Failure, Infection, Septic shock, Virus, Antibody, Pneumonia, Fungus, Lung, Mortality, Disease, Multiple organ dysfunction syndrome, Community-acquired pneumonia, Death, SCAP, CAP, COVID-19, Patient, Bacteria, Sepsis, Pharmaceutical industry

Biotest announced this week that the first hospitalized patient with Community-Acquired Pneumonia (CAP) has been treated in the multinational phase III TRICOVID trial.

Key Points: 
  • Biotest announced this week that the first hospitalized patient with Community-Acquired Pneumonia (CAP) has been treated in the multinational phase III TRICOVID trial.
  • The TRICOVID trial was already enrolling hospitalized patients with COVID-19 who require supplemental oxygen due to the severity of their disease.
  • However, trimodulin is not only expected to be effective in treatment of COVID-19 patients.
  • This further expedites the development of trimodulin as potential new treatment option for a broad population of hospitalized patients with CAP”, emphasized Dr Thomas Häder, Head of Clinical Strategy and Development at Biotest.

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Retrieved on: 
목요일, 11월 16, 2023
Multiple organ dysfunction syndrome, Primary biliary cholangitis, Permeability (electromagnetism), Hepatic encephalopathy, PBC, AASLD, IND, Disease, Mortality, Cirrhosis, Elafibranor, UCSF, Patient, Heart, Liver, ASK1, Caregiver, NTZ, Chronic liver disease, Cell death, MBA, MD, University, Transplant, Doctor of Philosophy, Microbiota, Fibrosis, Ipsen, University of California, European Foundation, Human, Inflammation, Pharmaceutical industry, ACLF, Hyperammonemia, Boston, Euronext

GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.

Key Points: 
  • GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.
  • ACLF is a potentially deadly, but reversible, condition in patients with chronic liver diseases, which is associated with multi-organ failure and high short-term mortality.
  • Pascal Prigent, CEO of GENFIT, commented: “During AASLD we were excited to further discuss our development strategy around our new pipeline focused on ACLF, where we believe multiple programs have the potential to transform the treatment paradigm for these patients.
  • As part of the “ACLF Day” event during AASLD, the critical need for treatment has been highlighted by leading experts in ACLF.

Venvalo Group Launches Immorta Bio, Inc Aimed at Providing Unlimited Personalized Cells for Treating Diseases of Aging and Treating Aging as Disease™

Retrieved on: 
수요일, 12월 6, 2023
Disease, Treating, CSO, Patient, Regenerative medicine, FDA, Multiple organ dysfunction syndrome, Heart failure, MIAMI, Liver failure, Cell, Pharmaceutical industry, Vaccine, Ageing

MIAMI BEACH, Fla., Dec. 6, 2023 /PRNewswire/ -- Venvalo Group announced today formation of Immorta Bio, Inc, a regenerative medicine company dedicated to providing patient specific therapeutic solutions for Treating Diseases of Aging and Treating Aging as Disease™.

Key Points: 
  • MIAMI BEACH, Fla., Dec. 6, 2023 /PRNewswire/ -- Venvalo Group announced today formation of Immorta Bio, Inc, a regenerative medicine company dedicated to providing patient specific therapeutic solutions for Treating Diseases of Aging and Treating Aging as Disease™.
  • "As we become older, a number of ailments accumulate, and it is inevitable that eventually you will succumb to one or a combination of those.
  • Solving the issue of diseases of aging is solving the aging itself," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio.
  • "We are developing personalized stem cell technologies that provide the greatest promise in the fight against diseases of aging."

EQS-News: Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation

Retrieved on: 
목요일, 12월 14, 2023
University College London, Community-acquired pneumonia, Ventilation, Intensive care medicine, Immunoglobulin A, Mortality, Inflammation, Multiple organ dysfunction syndrome, Plasma, Septic shock, COVID-19, CAP, Antibody, Patient, Oxygen, Sepsis, SCAP, Immunoglobulin M, Immunoglobulin G, Immune system, Failure, Pneumonia, Vaccine, Pharmaceutical industry

The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).

Key Points: 
  • The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).
  • One major characteristic of sCAP patients is that their immune system becomes dysregulated, which results in inflammation.
  • The results reported, support the currently ongoing investigation of trimodulin in artificial ventilated patients with sCAP with evidence of significant inflammation (ESsCAPE trial).
  • In addition, trimodulin is currently also in development for the treatment of hospitalized, oxygen-supported patients with non-severe CAP, including COVID-19 (TRICOVID trial).

FDA Grants Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device for Cardiorenal Syndrome

Retrieved on: 
금요일, 9월 29, 2023
Partnership, University, Heart failure, Heart, SCD, Food and Drug Administration, Center for Biologics Evaluation and Research, National Institutes of Health, Bangladesh Technical Education Board, AKI, Trial of the century, Șaeș, Acute kidney injury, PMA, MD, Patient, Multiple organ dysfunction syndrome, Cardiorenal syndrome, Breakthrough, Heart transplantation, LVAD, SeaStar, ICU, FDA, NIH, Food, Pharmaceutical industry, Research

The Breakthrough Device Designation is expected to expedite the clinical development and regulatory review of the SCD for use in this patient population.

Key Points: 
  • The Breakthrough Device Designation is expected to expedite the clinical development and regulatory review of the SCD for use in this patient population.
  • This is only the ninth Breakthrough Device Designation granted by the FDA’s Center for Biologics Evaluation and Research (CBER) since the program’s inception in 2015.
  • “Cardiorenal syndrome is seen in the most severe cases of heart failure and is associated with a very poor prognosis,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical.
  • “We believe the SCD represents a novel, innovative and transformative approach to treating hyperinflammation in severely ill patients with chronic heart failure.

EQS-News: Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin

Retrieved on: 
토요일, 9월 16, 2023
Multiple organ dysfunction syndrome, IMV, Failure, CAP, Oxygen, COVID-19, Immunoglobulin M, Immunoglobulin A, Inflammation, Septic shock, Sepsis, Plasma, Patient, Immunoglobulin G, Mortality, Bronchopneumonia, ICU, III, Pharmaceutical industry, SCAP

Biotest announced today that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit.

Key Points: 
  • Biotest announced today that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit.
  • This multinational phase III clinical trial is expected to enrol approximately 590 adult patients with severe Community Acquired Pneumonia (sCAP).
  • In the CIGMA trial a subgroup of patients with evidence of severe inflammation showed an encouraging reduction in the mortality rate when treated with trimodulin.
  • In addition to clinical development for sCAP, trimodulin is also currently in development for the treatment of COVID-19.